Barrigel, a NASHA spacer, helps to reduce radiation delivered to the rectum during prostate cancer radiation therapy. Credit: MattL_Images / Shutterstock.com.

Medical technologies provider Teleflex has signed a definitive agreement to take over Palette Life Sciences for an upfront cash deal of $600m.

Palette will also receive an additional $50m from Teleflex based on certain commercial milestone achievements.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the addition of non-animal stabilised hyaluronic acid (NASHA) spacer and tissue bulking products, the acquisition will broaden the Teleflex Interventional Urology portfolio, encompassing the UroLift System.

The new additions via the acquisition will help enhance patient outcomes in urology and urogynecology disorders, colorectal conditions and radiation oncology procedures.

Palette offers Barrigel, a NASHA spacer intended to reduce radiation delivered to the rectum during prostate cancer radiation therapy while enhancing tumour control.

Designed to be easily shaped, Barrigel is clearly visible on transrectal ultrasound and can be assembled in one step at any location. It is also biodegradable and reversible.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Palette’s portfolio also features Deflux and Solesta, the two NASHA-based tissue bulking agents specifically developed to address paediatric vesicoureteral reflux and faecal incontinence, respectively.

Teleflex chairman, president and CEO Liam Kelly said: “The acquisition of Palette Life Sciences will allow us to incorporate this exciting technology into our interventional urology business unit and bring urologists, radiation oncologists and other specialists more innovative technologies that can positively impact patient care.

“The transaction is consistent with our strategy to acquire assets that are accretive to Teleflex’s growth rate.”

Subject to customary closing conditions, the deal is expected to be completed in the fourth quarter of this year.